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Clostridioides difficile infection (CDI) accounts for a substantial proportion of deaths
attributable to antibiotic-resistant bacteria in the United States. Although C. difficile can be
an asymptomatic colonizer, its pathogenic potential is most commonly manifested in
patients with antibiotic-modified intestinal microbiomes. In a cohort of 186 hospitalized
patients, we showed that host and microbe-associated shifts in fecal metabolomes had the
potential to distinguish patients with CDI from those with non–C. difficile diarrhea and C.
difficile colonization. Patients with CDI exhibited a chemical signature of Stickland amino
acid fermentation that was distinct from those of uncolonized controls. This signature
suggested that C. difficile preferentially catabolizes branched chain amino acids during CDI.
Unexpectedly, we also identified a series of noncanonical, unsaturated bile acids that were
depleted in patients with CDI. These bile acids may derive from an extended hostmicrobiome dehydroxylation network in uninfected patients. Bile acid composition and
leucine fermentation defined a prototype metabolomic model with potential to distinguish
clinical CDI from asymptomatic C. difficile colonization.
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Clostridioides difficile infection (CDI) accounts for a substantial proportion of deaths attributable to antibiotic-resistant
bacteria in the United States. Although C. difficile can be an asymptomatic colonizer, its pathogenic potential is most
commonly manifested in patients with antibiotic-modified intestinal microbiomes. In a cohort of 186 hospitalized patients,
we showed that host and microbe-associated shifts in fecal metabolomes had the potential to distinguish patients with
CDI from those with non–C. difficile diarrhea and C. difficile colonization. Patients with CDI exhibited a chemical signature
of Stickland amino acid fermentation that was distinct from those of uncolonized controls. This signature suggested that
C. difficile preferentially catabolizes branched chain amino acids during CDI. Unexpectedly, we also identified a series of
noncanonical, unsaturated bile acids that were depleted in patients with CDI. These bile acids may derive from an extended
host-microbiome dehydroxylation network in uninfected patients. Bile acid composition and leucine fermentation defined a
prototype metabolomic model with potential to distinguish clinical CDI from asymptomatic C. difficile colonization.

Introduction

Each year in the United States, over 450,000 cases of Clostridioides
difficile infection (CDI) are associated with over 29,000 associated
deaths, with attributable costs of over $2 billion (1). CDI is the most
common healthcare-associated infection in US hospitals, and most
cases start outside of the hospital setting (2). Although antimicrobial exposures are clearly a critical CDI risk factor, the mechanisms
contributing to this association are incompletely understood.
CDIs arise following ingestion of C. difficile spores, which
germinate in the intestinal tract and give rise to metabolically
active, Gram-positive rods that colonize the colon. These vegetative forms secrete toxins whose effects upon the colonic epithelium give rise to a spectrum of intestinal symptoms ranging
from diarrhea to a life-threatening pseudomembranous colitis.
C. difficile persist with assistance from extensive antibiotic
resistance that enables proliferation in patients whose intestinal microbiomes have been altered by broad-spectrum antibiotic exposure. Individual differences in CDI susceptibility and
severity are also substantial, such that some patients harboring
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C. difficile do not benefit from C. difficile–directed antibiotic therapies (3, 4). The mechanistic bases for these individual
differences are poorly understood. Adaptations to different
chemical environments in the intestine may markedly affect
the pathogenic potential of C. difficile (5).
C. difficile is regarded as an opportunistic colonizer that is
susceptible to suppression by healthy intestinal microbiomes. A
number of candidate metabolic functions may contribute to this
suppressive activity (3). One such function is the ability of healthy
microbiomes to convert primary bile acids (e.g., cholic and chenodeoxycholic acids), which have been shown to promote spore
germination in vitro, to secondary bile acids (e.g., deoxycholic
and lithocholic acids, respectively). Both gnotobiotic or antibiotic-
exposed mice exhibit diminished secondary bile acid production,
though it is unclear which bile acid changes have causative, in
addition to correlative, relationships with CDI susceptibility in
humans (6–9). Recent work in an ex vivo murine model shows that
secondary bile acids inhibit C. difficile germination and growth,
although these effects are partially strain-specific (8, 9). Multiple
bile acid transformation pathways are plausible in humans, who
possess distinctive bile acids and microbiome compositions that
may contribute to CDI risk in species-specific ways.
Current approaches to CDI diagnosis require compatible laboratory findings in the context of attributable clinical symptoms
(e.g., diarrhea, abdominal pain, megacolon) (3). Two laboratory
diagnostic approaches currently predominate in US hospitals,
one based on nucleic acid amplification-based identification of
toxigenic C. difficile and the other based on enzyme immunoassay detection of C. difficile exotoxins. The relative merits of these
approaches have been debated (10). Direct detection of C. diffi-
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Table 1. Demographics of patient cohorts, including a summary
of C. difficile ribotypes
Characteristic

CDI (toxigenic
Asymptomatically
Not colonized
culture+, toxin EIA+) colonized (toxigenic (toxigenic culture–,
n = 62
culture+, toxin EIA–)
toxin EIA–)
n = 62
n = 62

Ward at stool collection
Ward
Oncology
ICU

50 (81%)
9 (15%)
3 (5%)

50 (81%)
9 (15%)
3 (5%)

50 (81%)
9 (15%)
3 (5%)

10 (16%)
20 (32%)
27 (44%)
5 (8%)
35 (57%)

17 (27%)
22 (36%)
21 (34%)
2 (3%)
35 (57%)

8 (13%)
19 (31%)
28 (45%)
7 (11%)
29 (47%)

49 (79%)
9 (15%)
0 (0%)
4 (7%)

37 (60%)
22 (36%)
1 (2%)
2 (3%)

44 (71%)
14 (23%)
1 (2%)
3 (5%)

62 (100%)
62 (100%)
26 (42%)

62 (100%)
61 (98%)
9 (15%)

NA
NA
NA

22 (36%)
11 (18%)
6 (10%)
4 (7%)
4 (7%)
3 (5%)
2 (3%)
2 (3%)
2 (3%)
1 (2%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
5 (8%)

8 (13%)
6 (10%)
1 (2%)
3 (5%)
6 (10%)
1 (2%)
9 (15%)
2 (3%)
4 (7%)
2 (3%)
4 (7%)
4 (7%)
2 (3%)
2 (3%)
8 (13%)

NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA

Age, categorical
≤45
>45–≤65
>65–≤85
>85

Female
Race
Caucasian
African American
Other
Unknown
Toxin status
Toxin A
Toxin B
Binary toxin

C. difficile strainA
027
106/174
WU27
002
001
WU8
014/020
017
WU2
WU30
WU36
075
015/046
070
Other strainB

C. difficile strain is given as ribotype (3 digits), or WU strain type if there
was no match to a Cardiff-ECDC collection ribotype strain. BListed as other
strain if only a single isolate was recovered.
A

cile (by culture or nucleic acid amplification) may be particularly
susceptible to false-positive results for CDI due to detection of
inactive spores, while there is concern that toxin detection tests
are insufficiently sensitive and may yield false-negative results in
some patients with CDI. Prospects for new approaches to improve
diagnostic accuracy are therefore of interest.
To better understand the relationship between the intestinal
metabolome and CDI in humans, we conducted fecal metabolomic profiling of hospitalized patients with diarrheal symptoms
at an academic medical center. The cohort consists of patients
with a toxigenic culture positive for C. difficile, either with or

without a positive toxin enzyme immunoassay (EIA) result,
alongside matched, uncolonized controls. To characterize fecal
metabolomes, we used untargeted gas chromatography–mass
spectrometry (GC-MS), which permits robust chemical identification of metabolites and dietary compounds. Using multivariate analyses, we resolved multiple CDI-associated metabolites
with microbial, host, and dietary origins. A distinctive short
chain fatty acid (SCFA) series implicates extensive anaerobic
amino acid metabolism by C. difficile in some colonized subjects.
A novel, noncanonical bile acid correlation network not previously described in CDI susceptibility was also resolved. These
and other results are consistent with numerous host-pathogen
interactions that shape the relationship between patients and
C. difficile. This allowed us to assemble a metabolomic definition
of CDI from biochemical indices based on C. difficile–associated
amino acid fermentation and host bile acid metabolism. These
results may direct new CDI therapeutic and diagnostic efforts
toward clinically relevant targets.

Results

Clinical cohort. Diarrheal specimens meeting inclusion and exclusion criteria were cultured for C. difficile. All C. difficile isolates
recovered in culture were characterized for the presence of toxins
tcdA, tcdB, cdtA, and cdtB by multiplex PCR, and underwent PCR
ribotyping as previously described (11–14). Of the 8931 available
stool specimens (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/
JCI126905DS1), 2829 were eligible for chart review, through
which an additional 2206 were excluded, yielding 622 stool specimens meeting inclusion and exclusion criteria. From these specimens, we assembled a 186-person cohort split into 3 groups of 62
patients matched by age and hospital location. These groups were
defined by laboratory results: toxigenic culture–positive and toxin
enzyme immunoassay–positive (using the Wample/TechLab Tox
A/B II assay during routine clinical testing, Cx+/EIA+), toxigenic
culture–positive and toxin enzyme immunoassay–negative (Cx+/
EIA–), and toxigenic culture–negative and toxin enzyme immunoassay–negative (Cx–/EIA–) controls. Cohort demographics and
clinical characteristics are shown in Table 1.
Fecal metabolome characteristics. To characterize fecal metabolomic variations in the study cohort, we detected and quantified
trimethylsilyl-derivatized fecal extracts using GC-MS. GC-MS is
sensitive to low-molecular-weight analytes and does not detect
proteins, peptides, complex lipids, or other macromolecules. We
detected ions produced by electron ionization (EI), which oftentimes provides sufficient structure information to chemically identify metabolites of interest. Fecal metabolites may originate from
human cells, microbiome, and/or diet. To compare metabolomes
between specimens in the study population, GC-MS profiles were
aligned so that each analyte (hereafter called a feature) is defined
by its characteristic EI mass spectrum and GC retention time.
Within the 186 patient specimens, we detected 2540 distinct features, 77 of which were removed as contaminants because they
were present at comparable levels in multiple blank controls, leaving 2463 features for metabolomic analyses. These features were
sparsely distributed with a heavy tail (Figure 1A), with only 593 features appearing in at least 8 (5%) specimens. The number of molecjci.org   Volume 129   Number 9   September 2019
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Figure 1. Metabolomic characteristics of the patient
cohort. (A) Histogram showing the distribution of
feature richness (number of features present per
sample) across all patient specimens. (B) Histogram
showing the number of samples within which each
unique feature is present. Fecal metabolomes were
highly individualistic: among the more than 2000
features detected, most were infrequent. While the
resulting data are very sparse overall, the distribution
has a relatively heavy tail with a few features present
in many samples. (C) Principal component analysis
(PCA) score plot across the first 2 components created using log-transformed feature intensities across
all metabolomic features. (D) PCA does not appear to
reveal dominant modes of variation, with no single
component explaining more than 9% of the variance
and a long tail of modes each explaining approximately 1% each.

ular features per sample was approximately normally distributed
(Figure 1B; mean 164 features, standard deviation 54 features).
Principal component analysis (PCA) of log-transformed feature
intensities revealed no dominant modes of variation, with the first
principal component explaining less than 10% of the overall variance in the data (Figure 1, C and D). Fecal metabolomes defined by
GC-MS thus exhibit a high degree of individual variation, with only
a small minority of metabolites common to all subjects.
Metabolomic differences between C. difficile–infected and uninfected controls. To identify CDI-associated fecal metabolites, we
conducted a supervised multivariate comparison of Cx+/EIA+ and
Cx–/EIA– specimens. We used Cx+/EIA+ specimens to represent
CDI because they harbor viable, toxigenic C. difficile alongside
evidence of concurrent toxin production. Given the chemical complexity of fecal metabolomes (the >2000 resolved features greatly exceed the 124 samples), we employed multiple complementary measures to avoid overfitting the data, including repeated
cross-validation (see Methods). Sparse partial least squares-discriminatory analysis (sPLS-DA) (Figure 2A) demonstrates good
separation between metabolite profiles from the Cx+/EIA+ and
Cx–/EIA– groups, despite this model’s use of an explicit penalty
to prevent overfitting. To further assess this relationship, we conducted a separate logistic regression analysis on the Cx+/EIA+ and
Cx–/EIA– groups with a similar penalization parameter to avoid
overfitting. Using repeated 5-fold cross-validation with random
subsets to select an appropriate penalization level, we found that
3794
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relatively few molecular features yielded a large jump in average
accuracy of the regression model (Figure 2B). We fixed the penalty
parameter to the value yielding the maximum percent predicted,
indicated by the star in Figure 2B, and again performed penalized
logistic regression fit to the Cx+/EIA+ and Cx–/EIA– groups with
repeated randomized 5-fold cross-validation. The observed distributions of log-odds for the test folds (that is, excluding the training sets) for Cx+/EIA+ and Cx–/EIA– again demonstrate good separation (Figure 2C). For comparison, Figure 2C also includes the
distributions of the log-odds values for the Cx+/EIA– cases. The 9
metabolite features most consistently associated with Cx+/EIA+
specimens (Table 2 and Supplemental Table 1) include both positive and negative associations. The features consist of 2 SCFAs,
1 amino acid, 1 bile acid, 1 lipid, 3 carbohydrates, and 1 aromatic alcohol. These results implicate biochemically diverse metabolites in human CDI pathogenesis. We then fit a logistic model
using only the 6 features that were most frequently selected across
the cross-validation runs. This model achieves a ROC AUC (area
under the receiver-operator characteristic curve) of 96.7%, with a
95% confidence interval of 85.6%–100% obtained under repeated
randomized 5-fold cross-validation (Figure 2D). These results are
consistent with a strong, characteristic signal that distinguishes
Cx+/EIA+ specimens from Cx–/EIA– controls.
Stickland amino acid fermentation in CDI. Among the
most highly CDI-associated metabolites (Table 2) is the SCFA
4-methylpentanoic acid (4-MPA/4-methylvaleric acid/iso-
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Figure 2. Supervised metabolomic analyses comparing Cx+/EIA+ with Cx–/EIA– samples. (A) Observed separation of Cx+/EIA+ and Cx–/EIA– samples under
sparse partial least squares–discriminatory analysis (sPLS-DA). The data ellipses are drawn around each group of samples (at the 95% level). (B) Penalized
logistic regression under repeated 5-fold cross-validation shows how the number of features used relates to the obtained accuracy, yielding high accuracy
with a relatively small number of features. The maximum percent predicted is indicated by a star. (C) Using the penalty parameter associated with the
maximum percent predicted, penalized logistic regression demonstrates good separation in the distribution of log-odds to be classified Cx+/EIA+ versus
Cx–/EIA–. In the log-odds distribution shown here, only the test folds of Cx+/EIA+ and Cx–/EIA– for each randomized cross-validated run are shown (that is,
the corresponding distribution of the training set is not shown). For comparison, the corresponding log-odds of the Cx+/EIA– samples are also shown.
(D) Logistic regression (without penalty) to classify Cx+/EIA+ versus Cx–/EIA– was performed using only the 6 features most frequently used in the penalized logistic regressions. Fitting to all samples gives 96.7% ROC AUC. The 95% CI of 85.6%–100% AUC was obtained under repeated randomized 5-fold
cross-validation using the same 6 features.

caproic acid). Unlike the SCFAs formate, acetate, and butyrate,
which are produced during microbial carbohydrate fermentation, 4-MPA is produced from leucine through the Stickland
reactions, amino acid fermentation pathways associated with C.
difficile and other anaerobic bacteria (15–24). Ten established
Stickland products were detected in the study cohort, representing both oxidative and reductive fermentation of 8 different
amino acid precursors (Figure 3A and Supplemental Figure 2).
These products exhibit varying degrees of association with CDI,
with 8 of 10 products (80%) detected more frequently in CDI
specimens than controls (Figure 3B and Supplemental Figure 5).
Many Stickland products were present in Cx–/EIA– specimens,
consistent with production by bacteria other than toxigenic C.
difficile. Bootstrapped logistic regression (fit on 2000 bootstrap
samples, stratified on Cx/EIA status) of Stickland metabolites
consistently assigns the highest odds ratios for CDI to 4-MPA,
the end product of leucine reduction (Figure 3C). Although

other canonical Stickland products like 5-aminopentanoic acid
(5-aminovaleric acid) are frequently present in CDI, they offer
negligible discriminatory power beyond that of 4-MPA in the
adjusted analysis.
To more precisely quantify the relationship between 4-MPA
production and CDI, we devised a targeted GC-MS assay to quantify Stickland fermentation activity through product/precursor
ratios. In addition to increasing assay sensitivity and precision,
this targeted biomarker ratio is intrinsically insensitive to the variations in fecal dilution that characterize diarrheal specimens. In
an arbitrary subset of matched specimens, the 4-MPA/leucine
ratio varied significantly between groups (P = 1.3 × 10–8, Kruskal-Wallis test). This variation distinguishes Cx+/EIA+ specimens
from Cx–/EIA– specimens with an ROC AUC of 92.8% (95% CI:
86.8%–98.7%; Figure 4, A and B) that rivals the 6-feature regression model described above and in the Methods (Figure 2D; AUC
= 96.7%; 95% CI: 85.6%–100%).
jci.org   Volume 129   Number 9   September 2019
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Table 2. Top CDI-associated metabolites selected during cross-validation of logistic regression model
Feature (mass@RT)
173.0@4.71
117.0@4.70
159.0@7.55
86.0@6.755
215.0@24.80
73.0@13.79
67.0@20.17
179.0@12.06
204.0@19.45
217.0@14.72

FrequencyA

Median odds ratio (95% CI)

Metabolite

Class

100%
99%
99%
98%
96%
95%
94%
94%
91%
89%

1.54 (1.41–1.69)
1.16 (1.04–1.30)
1.12 (1.02–1.25)
0.91 (0.84–0.98)
0.87 (0.78–0.98)
0.92 (0.83–0.99)
1.11 (1.01–1.24)
1.15 (1.02–1.27)
0.87 (0.77–0.98)
0.93 (0.84–0.99)

4-methylpentanoic acid, TMS derivativeB
4-methylpentanoic acid, TMS derivativeB
2-hydroxy-4-methylpentanoic acid
Isoleucine
Cholenoic acid
Ribitol
Eicosatrienoic acid
Tyrosol, 2TMS derivative
Glyceryl glycoside
Fructose

SCFA
SCFA
SCFA
Amino acid
Bile acid
Carbohydrate
Lipid
Aromatic alcohol
Carbohydrate
Carbohydrate

Proportion of cross-validation models including the metabolite. BTwo ions from same metabolite were independently resolved.

A

Together, these results are consistent with a pathophysiologic role for Stickland fermentation in CDI. While the presence of
these metabolites in Cx–/EIA– specimens suggests that intestinal
Stickland metabolism in patients is not generally unique to CDI,
the selective increase in 4-MPA in CDI specimens raises the possibility that leucine reduction is a selectively emphasized pathway
in C. difficile during clinical infections.
The isomeric amino acid allo-isoleucine is associated with CDI.
Among the metabolites that are positively associated with CDI
is allo-isoleucine, an isoleucine diastereomer in which the beta
carbon stereocenter is inverted from an S to an R configuration
(Figure 5A). This noncanonical, nonproteinogenic amino acid has
been identified as a biomarker of branched chain ketoaciduria
(maple syrup urine disease, an inborn error of metabolism) but
has not previously been associated with C. difficile or CDI. Its origins in feces are unclear, although a previously reported bacterial
metabolic pathway producing it from L-isoleucine raises the possibility that it derives from the intestinal microbiome (25). To more
carefully assess the relationship between allo-isoleucine and CDI,
we devised a targeted GC-MS assay to quantify allo-isoleucine as
a ratio to isoleucine, its putative precursor. The allo-isoleucine-toisoleucine ratio varied significantly between groups (P = 6.5 × 10–5,
Kruskal-Wallis test; Figure 5B and Supplemental Figures 3 and 4).
ROC analysis (Figure 5C) (AUC = 79.7%; 95% CI: 68.2%–91.3%)
suggested favorable diagnostic potential for distinguishing Cx+/
EIA+ specimens from Cx–/EIA– specimens. These observations
identify allo-isoleucine as a new and biochemically distinctive
CDI correlate of unclear origin.
Bile acid metabolic pathways active in patients without CDI. Three
negatively loaded bile acid features are among the most frequently
detected Cx+/EIA+ correlates in our cross-validated analysis (Table
2 and Supplemental Table 1). This corresponds to previous scholarship, which has associated bile acid dehydroxylation by the intestinal
microbiota with CDI susceptibility (6, 7, 26, 27). Canonical bile acid
processing by the microbiome involves successive dehydroxylation of
cholic acid (CA; a tri-hydroxylated primary bile acid) to deoxycholic
(DCA, a di-hydroxylated secondary bile acid) and chenodeoxycholic
acid (CDCA; a di-hydroxylated primary bile acid) to lithocholic acid
(LCA, a mono-hydroxylated secondary bile acid). Unexpectedly, the
2 most highly CDI-associated bile acids in our cohort were identified
3796
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as cholenoic acid and monohydroxycholenoic acid (CE and MHCE,
respectively, Supplemental Figures 6–11), noncanonical unsaturated, dehydroxylated bile acids. As with DCA and LCA, these bile
acids were more abundant in the non-CDI group, consistent with an
alternative bile acid dehydroxylation pathway based on dehydration
reactions (net loss of H2O to yield a double bond).
Unsaturated, nonhydroxylated bile acids are seldom considered in the bile acid literature. Their absence from our metabolite
database compelled us to identify them through manual interpretation of spectra and comparison to chemically related reference
compounds (Supplemental Figures 6–11). CE, a nonhydroxylated,
unsaturated bile acid, was previously identified by Robben et al.
as a lithocholic acid sulfate (LCA-S) desulfation product generated
by an intestinal isolate of the Bacteroidaceae family (28). Robben
et al. noted 2 isomeric CE products of these bacteria that differ
in double bond location. We similarly observed 2 closely eluting
CE products, consistent with a similar product distribution in our
patient cohort (Supplemental Figure 9). Human tissues are known
to generate sulfated bile acids, including LCA-S, which may provide substrates for fecal CE production through enzymatic desulfation (29). These observations are consistent with diminished
microbial bile acid desulfation activity in patients with CDI.
Identification of a CDI-associated human bile acid network.
Based on the presence of CE and MHCE in patient specimens, we
hypothesized that sulfated bile acids (the precursors of unsaturated bile acids) (28) are also present. We further hypothesized that
the desulfation mechanism of unsaturated bile acid production
is generalizable such that an extended series of bile acid sulfates
and unsaturated bile acids are present in the human fecal metabolome (Figure 6B). Using the calculated molecular weights, MS/
MS fragmentation patterns, and chromatographic elution ranges
for these hypothesized bile acids, we constructed a liquid chromatography–tandem mass spectrometry (LC-MS/MS) assay (Supplemental Figures 12–14 and Supplemental Table 4) because sulfated
bile acids are undetectable by GC-MS. This assay resulted in tentative detection of 14 sulfated bile acids, 6 of which were dehydrogenated (possessing either an alkene or ketone; Table 3 and ref.
30). Many of these bile acids are distinguishable only by retention
time, consistent with isomers that differ in the position(s) of double bonds, hydroxyl groups, and/or sulfate.

The Journal of Clinical Investigation  
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Figure 3. Amino acid metabolism in C. difficile. (A) Stickland metabolism consists of anaerobic amino acid fermentation through coupled oxidation and reduction
pathways. In the reductive pathway, amino acids are first deaminated to form 2-hydroxy acids and then reduced to carboxylic acids. In the oxidative pathway, amino acids are deaminated and oxidized with loss of CO2 to yield a distinct set of carboxylic acids. Depicted here are established Stickland substrates and products
identified within patient fecal metabolomes. Stickland substrates include the nonproteinogenic amino acid ornithine. ND, not determined. (B) Heatmap of Stickland precursor and product abundances corresponding to patient fecal metabolomes from the 3 diagnostic groups. Metabolites were organized using unsupervised hierarchical clustering. Metabolites differing significantly (Mann-Whitney U test; *P < 0.05, ***P < 0.001) between Cx–/EIA– and Cx+/EIA+ groups are labeled,
along with the direction of the difference relative to the Cx–/EIA– control group. Stickland products are labeled according to the color scheme in A. (C) Adjusted and
unadjusted (crude) CDI odds ratios and confidence intervals (95%) for Stickland precursors and products. Odds ratios were estimate by fitting logistic regression
models to each of 2000 bootstrap samples stratified on Cx/EIA status (Cx–/EIA– vs. Cx+/EIA+). Logistic models containing a single metabolite were fit to obtain
crude odds ratios (red). A single logistic model including all metabolites was fit to obtain the adjusted odds ratios (green). Bars represent 95% bootstrap percentile
confidence intervals and black dots represent median odds ratios across all bootstrap samples. Stickland products are labeled according to the color scheme in A.

Although fecal bile acids largely originate from 2 primary bile
acids (CA and CDCA), subsequent host conjugation, divergent
microbiome cometabolism, and enterohepatic circulation create a
complex, nonlinear bile acid physiology. To characterize bile acid
interrelationships, we therefore performed community detection

(31) on the weighted network of positive correlations among the 14
noncanonical bile acids described above and 17 canonical conjugated and nonconjugated primary and secondary bile acids. Seven
bile acid communities emerged from this unbiased network community detection analysis, many of which could be rationalized by
jci.org   Volume 129   Number 9   September 2019
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Figure 4. 4-MPA/leucine ratio elevated in CDI. (A) Dot plots of 4-MPA/
leucine product/precursor ratios measured by targeted (SIM) reanalysis
of fecal specimens (n = 32 for each group). Patient groups were compared
using the Kruskal-Wallis test (P = 1.3 × 10–8). To further characterize
pair-wise differences between groups, Bonferroni-corrected Mann-Whitney U test P values are indicated (3 comparisons; NS: P ≥ 0.05, ***P <
0.001). Ratio thresholds giving perfect specificity (0.0825, black star) or
sensitivity (0.00132, white star) for CDI+/EIA+ are marked as gray dashed
lines. (B) Receiver-operator characteristic (ROC) plot distinguishing Cx+/
EIA+ patients from Cx–/EIA– patients. The gray region represents the
bootstrapped 95% confidence interval for the true-positive rate at each
false-positive rate. Thresholds with perfect specificity or sensitivity are
marked by stars, as in A.

shared chemical features (Table 3 and Figure 6A). Where unavailability of authentic internal standards prevents identification of
hydroxylation sites (e.g., the 3, 7, and 12 carbon positions) or epimers, bile acids are designated with general names. Communities
1 to 3 are composed exclusively of canonical primary and secondary bile acids. Community 1 consists of classic primary bile acids
while community 2 consists of their glycine or taurine conjugates.
Community 3 consists of conjugated secondary (dehydroxylated)
bile acids. Community 4 includes secondary bile acids, secondary bile acid sulfates, and 1 candidate di-hydroxylated cholenic
acid sulfate. Communities 5 and 6 consist entirely of sulfated bile
acids, with a single sulfated cholenic acid candidate. The 5 bile
acids in community 7 are all sulfated, with 4 cholenic acid sulfate
candidates. The 5 candidate dehydroxylated cholenic acid sulfates
may plausibly include sulfated keto bile acids, secondary bile acids
of identical mass. In a force-directed layout depicting this network
(Figure 6A), the primary bile acids (CA, CDCA) are located centrally, consistent with their recognized roles as precursors to conjugated and secondary bile acids. Clockwise progression moves
from bile acid communities defined by host glycine and taurine
conjugation, to classical microbial dehydroxylation, to sulfation,
to desaturation or ketone formation (Figure 6B). The community
organization emerging from this analysis reflects the distinctive
metabolic transformations identified in the present study and in
previous work.
Bile acid metabolomic associations with CDI. Disruption of
microbiome-mediated bile acid metabolism has long been regarded to increase CDI risk. In our inpatient cohort, we hypothesized
that the Cx–/EIA– group includes a subset of patients with disrupted, CDI-susceptible microbiomes. To test this hypothesis, we used
PCA to graphically summarize bile acid metabolomic variation in
culture-negative specimens (Figure 7, A and B). Next, we projected Cx+/EIA+ bile acid profiles onto these principal components.
Consistent with the hypothesis, Cx+/EIA+ specimens preferentialFigure 5. Isoleucine isomer correlated with C. difficile. (A) Chemical
structures of isoleucine and its diastereomer, allo-isoleucine. (B) Dot plot
of allo-isoleucine/isoleucine ratios as measured by SIM (n = 32 for each
group). Patient groups were compared using the Kruskal-Wallis test (P =
6.5 × 10–5). To further characterize pair-wise differences between groups,
Bonferroni-corrected Mann-Whitney U test P values are indicated (3
comparisons; NS: P ≥ 0.05, ***P < 0.001). (C) ROC plot showing ability
to distinguish Cx+/EIA+ patients from Cx–/EIA– patients. The gray region
represents the bootstrapped 95% confidence interval for the true-positive
rate at each false-positive rate.
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ly occupied a restricted portion of the Cx–/EIA– patient bile acid
profile distribution. Specifically, Cx+/EIA+ specimens preferentially exhibit elevated values along the first PCA-derived principal
component (PC1). High PC1 scores correspond to higher primary
(cholic and chenodeoxycholic) and low secondary (deoxycholic
and lithocholic) bile acids (Figure 7D), similar to previous studies (26, 27). Low PC1 scores correspond to higher levels of sulfated and dehydroxylated cholenic and cholanic acids (DHCA-S3,
DHCE-S3, LCA from community 4). ROC analysis using PC1 as
the discriminator revealed an AUC of 61.3% (Figure 7C). These
results are consistent with a negative association between CDI
and bile acid sulfation, dehydroxylation, and unsaturation. While
we cannot conclude a causative role from these correlative data,
these metabolic processes may indicate the presence of a CDI-resistant intestinal microbiome.
Fecal carbohydrate associations with CDI. We next hypothesized
that the Cx–/EIA– group includes patients with CDI-susceptible
intestinal metabolites other than bile acids. To test this hypothesis, we used PCA to graphically summarize total GC-MS detectable metabolomic variation in culture-negative specimens. Next,
we projected CDI patient metabolomes onto these principal components. Consistent with the hypothesis, CDI patient fecal metabolomes occupy a restricted portion of the uncolonized patient
distribution, characterized by a high PC1 score (Figure 8, A and
B). ROC analyses of PC1 scores yielded a modest AUC of 61.1%
when distinguishing Cx+/EIA+ from Cx–/EIA– specimens (Figure
8C). These metabolites are not clearly related to bile acid compo-
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Figure 6. Bile acid transformations in the clinical cohort. (A) A force-directed
network layout illustrates associations between bile acids in the study cohort.
Each node represents a bile acid and each connecting line (edge) represents
an association between 2 bile acids as 1 of the 5 highest correlations for at
least 1 of the corresponding nodes. Edge lengths are determined by the level
of correlation between connected bile acids. Nodes are colored by community assignment. (B) Scheme showing metabolic transformations producing
bile acids in the network analysis. The central structure highlighted in gray
represents a tri-hydroxylated primary bile acid (e.g., cholic acid). Taurine or
glycine conjugation forms peptide bonds to the carboxylic acid group (right).
Alcohol groups are removed from the bile acid nucleus (dehydroxylation,
bottom right) or oxidized to a ketone (top left). Bile acid sulfation involves
substitution of an alcohol group with a sulfate (R = SO4–) group (bottom left).
Desulfation of bile acid sulfates yields unsaturated bile acids (left).

sition, since the total metabolome PC1 exhibits a low degree of
association with the bile acid PC1 determined above (r2 < 0.007;
Supplemental Figure 17). Instead, high PC1 scores are primarily
characterized by diminished monosaccharides, disaccharides,
and sugar alcohols with uncertain relationships to CDI (Figure 8D
and Supplemental Figure 16). While these metabolite classes can
be reasonably identified by GC-MS, identifying specific isomers is
often unreliable (e.g., sorbitol and mannitol are both C6H14O6 and
differ only in the orientation of 1 hydroxyl group and yield comparable spectra). The monosaccharide fructose, a favored C. difficile
carbon substrate (32), emerged as a negative CDI correlate in the
logistic regression analysis above (Table 2), raising the possibility that some carbohydrates may be consumed by metabolically
active C. difficile. Trehalose, a disaccharide recently reported to
be a favored substrate of epidemic C. difficile ribotypes 027 and
078, was not identified in our differential analysis (33). To more
carefully assess the relationship between trehalose and CDI, we
quantified fecal trehalose using a targeted GC-MS analysis based
on stable isotope dilution with a 13C6-labeled internal standard
(Supplemental Figure 15). It was detectable in 61% (115/189) of
specimens but did not distinguish Cx+/EIA+ from Cx–/EIA– specimens (35/63 vs. 41/63, P = 0.36, 2-tailed Fisher’s exact test). In
027-positive specimens, trehalose also did not distinguish toxin-positive from toxin-negative specimens (6/8 vs. 12/23, P = 0.41,
2-tailed Fisher’s exact test). A subset of fecal carbohydrates thus
has some potential to distinguish CDI and possibly CDI-susceptible patients, though the basis for this remains unclear.
A metabolomic model of CDI. To determine whether fecal Stickland metabolites and bile acids can be used to construct a metabolomic definition of CDI, we conducted logistic regression using
the 4-MPA/leucine ratio (log10-transformed) and the bile acid PC1
(Table 4 and Figure 9A). Each parameter alone exhibited significant
(P < 0.05) independent associations with Cx+/EIA+ status when compared with Cx–/EIA– specimens. When the logistic model criterion is

applied (corresponding to >50% probability), Cx+/EIA+ specimens
clustered in the high 4-MPA/leucine and high bile acid PC1 quadrant (Figure 9, A and B). ROC analysis of this model yields an AUC
of 98.2%, out-performing the original 6-feature model described
above (Figure 9C). Each parameter contributed independently—
adding a term for interaction between 4-MPA/leucine ratio and bile
acid PC1 did not significantly improve the logistic model (P = 0.53,
analysis of deviance). These results are consistent with distinctive
host and microbial metabolic processes in human CDI.
Metabolomic differences in colonized patients with and without
detectable fecal toxin. To determine whether Cx+/EIA– specimens
possess distinctive metabolomes, we compared 4-MPA/leucine
and bile acid composition profiles from Cx+/EIA– specimens to
those of Cx+/EIA+ or Cx–/EIA– specimens. In the logistic regression
model, only 38% (20/32) resembled Cx+/EIA+ specimens, with the
remainder exhibiting low 4-MPA/leucine ratios in specimens with
or without susceptible bile acid profiles (Figure 9, A and B). These
observations are consistent with low C. difficile metabolic activity
and a protective bile acid profile in many patients with undetectable fecal toxin. Using the logistic regression parameter compared
with toxigenic culture or toxin EIA results alone defines a positive
test group that is smaller than (but almost entirely encompassed
by) toxigenic culture–positive specimens but greater than the
number of toxin EIA–positive specimens (Figure 9D). If the metabolic criterion is highly accurate, it may restrict false-positive
results from toxigenic C. difficile detection alone and also restrict
false-negative results from the toxin EIA test. Further study is necessary to determine whether this possibility can be realized.

Discussion

In this study, we compared the fecal metabolomic profiles from
186 hospitalized patients to investigate relationships between
fecal metabolites, the presence of toxigenic C. difficile, and the
presence of detectable C. difficile toxins. Untargeted metabolomic
profiling in the context of uncontrolled patient dietary and microbiome contributions yielded extremely diverse fecal metabolomes. Nevertheless, numerous CDI-associated metabolites were
resolved. Among the 2463 features detected in this cohort, 43 had
some ability to resolve CDI from uncolonized controls. Many of
these discriminatory molecules are associated with Stickland and
bile acid metabolism, processes previously implicated in CDI
pathogenesis (6–9, 18, 19, 23, 26, 27, 34, 35). The specific molecular signatures best able to resolve CDI from controls exhibit only
jci.org   Volume 129   Number 9   September 2019
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Table 3. Fecal bile acids monitored by LC-MS/MS
CommunityA

Abbreviation

NameB

1

CA
MCA
CDCA
UDCA
G-CA
T-CA
HDCA
G-CDCA
G-UDCA
T-CDCA
T-UDCA
G-DCA
T-DCA
T-LCA
G-LCA
DCA
LCA
DHCA-S3
DHCE-S3
MHCA-S2
LCA-S
DHCE-S5
DHCA-S2
DHCA-S5
DHCA-S1
DHCA-S4
DHCE-S1
DHCE-S2
DHCE-S4
MHCA-S1
MHCE-S1

Cholic acid
α-Muricholic acid
Chenodeoxycholic acid
Ursodeoxycholic acid
Glycocholic acid
Taurocholic acid
Hyodeoxycholic acid
Glycochenodeoxycholic acid
Glycoursodeoxycholic acid
Taurochenodeoxycholic acid
Tauroursodeoxycholic acid
Glycodeoxycholic acid
Taurodeoxycholic acid
Taurolithocholic acid
Glycolithocholic acid
Deoxycholic acid
Lithocholic acid
Dihydroxycholanic acid sulfate-3
Dihydroxycholenic acid sulfate-3D
Monohydroxycholanic acid sulfate-2
Lithocholic acid sulfate
Dihydroxycholenic acid sulfate-5D
Dihydroxycholanic acid sulfate-2
Dihydroxycholanic acid sulfate-5
Dihydroxycholanic acid sulfate-1
Dihydroxycholanic acid sulfate-4
Dihydroxycholenic acid sulfate-1D
Dihydroxycholenic acid sulfate-2D
Dihydroxycholenic acid sulfate-4D
Monohydroxycholanic acid sulfate-1
Monohydroxycholenic acid sulfate-1

2

3

4

5

6
7

PrimaryC

Hydroxylations,
no.

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

3
3
2
2
3
3
2
2
2
2
2
2
2
1
1
2
1
2
2
1
1
2
2
2
2
2
2
2
2
1
1

Conjugation,
type

Sulfate

Unsaturated

Glyco
Tauro
Glyco
Glyco
Tauro
Tauro
Glyco
Tauro
Tauro
Glyco

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Yes

Yes

Yes
Yes
Yes
Yes

Bile acids monitored by LC-MS are listed in order of community assignment (Figure 6). Where a reference standard is available to confirm chemical
identity, the common name is used. Where lack of a reference standard prevents isomeric assignment, a candidate chemical structure is provided in italics.
C
Bile acids are marked “primary” if they have a known host biosynthetic origin. DAlternatively, structure may include a keto group.
A

B

partial overlap with those identified in prior metabolomic studies
using mouse models, which may reflect species differences, the
presence of a variable host microbiome background, and the specific mass spectrometric approach. Toxin-negative, toxigenic C.
difficile–positive (Cx+/EIA–) specimen metabolomes span a metabolomic continuum ranging from control-like to CDI-like. Among
Cx+ specimens, fecal metabolites have the potential to distinguish
infected from colonized patients.
Identification of 4-MPA as the most prominent CDI correlate
is consistent with its production by C. difficile from leucine during
Stickland metabolism. Other Stickland products were also detected and observed to be elevated in patients with CDI, although their
abundance among the control specimens (Cx–/EIA–) diminished
some of their associations (low positive predictive value), especially that of 5-aminopentanoic acid. This contrasts with previously
reported murine studies in which multiple Stickland metabolites
are highly CDI-associated. The discrepancy between patient and
mouse studies likely arises from Stickland-metabolizing organisms
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in Cx–/EIA– patient microbiomes, which may be limited or absent
in the antibiotic-treated mice used in experimental CDI models.
4-MPA has not been uniformly identified as a CDI correlate in
metabolomic studies of murine CDI. This may reflect host-associated substrate selection of leucine for Stickland metabolism by toxin-producing C. difficile but may also reflect lack of detection due to
the apparent insensitivity of typical untargeted LC-MS approaches
to 4-MPA (unpublished observations). Indeed, GC-MS remains a
favored modality for SCFA analyses by many investigators. Nevertheless, the implication of Stickland fermentation in CDI is generally consistent with previous human and animal model studies.
The association between Stickland fermentation and CDI is
consistent with the hypothesis that fecal amino acid availability
enhances CDI susceptibility. Our data do not rule out an important role for carbohydrate metabolism, the C. difficile fermentation
products of which (pyruvate, formate, acetate, butyrate) are less
distinctive than Stickland metabolites (18). Although we observed
no association between CDI and fecal trehalose, a glucose disac-
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Figure 7. The bile acid distribution in patients with CDI resembles that of a characteristic subgroup of uninfected, hospitalized patients. (A) Depicted
here is a PCA plot of uninfected patients’ bile acid profiles (green, n = 62). Onto this space, we projected the bile acid metabolome of patients with CDI
(red, n = 62). Data ellipses are drawn around each group of samples (95% level). Clustering of CDI specimens at high PC1 values is consistent with a favored
bile acid distribution among patients with CDI. (B) Dot plot of PC1 scores for each patient sample (n = 62 in each group). Gray dashed line represents optimal PC1 threshold for distinguishing Cx–/EIA– from Cx+/EIA+ samples. This threshold was chosen by maximizing the sum of percent sensitivity and specificity. (C) ROC plot evaluating the ability of PC1 to distinguish CDI patients from controls. The gray region represents the bootstrapped 95% confidence
interval for the true-positive rate at each false-positive rate. An asterisk marks the point corresponding to the optimal PC1 threshold depicted in B. (D) PCA
loading plot depicting the relative contributions of each bile acid to the distribution of Cx–/EIA– samples in A. Abbreviations are indicated in Table 3.

charide generated during bacterial stress responses, utilized as a
food additive, and proposed as a dietary risk factor for CDI caused
by hypervirulent strains (ribotype 027; Table 1), the other fecal carbohydrates detected in this study may plausibly serve as metabolic
substrates (33). A recent study by Battaglioli et al. observed a broad
spectrum increase in fecal amino acid concentrations in gnotobiotic mice colonized with dysbiotic human gut microbiota. This
increase corresponded to high fecal C. difficile colonization after
experimental challenge (35). In the present study, amino acids tend
to be diminished in CDI specimens compared with controls (Figure
3, B and C, and Supplemental Figure 18). This apparent contradiction may be reconciled by interpreting the decrease in amino acids
during CDI as evidence of consumption by metabolically active C.
difficile, which yields the aforementioned Stickland products. The
importance of amino acid substrate selection by C. difficile during
clinical CDI remains unclear. The present data are consistent with
a preference for branched chain amino acids (leucine, isoleucine,
and valine) relative to other intestinal microbes, though it is possible that other Stickland substrates, such as proline, tyrosine,
phenylalanine, and ornithine, could substitute for branched chain
amino acid deficiencies. If so, gut microbiota that deplete a broad
range of fecal amino acids may help hosts resist CDI.

In addition to implicating C. difficile metabolic pathways in
CDI patients, the present study also identifies a series of CDI-associated bile acids. Previous mouse model studies have identified
associations between diminished fecal secondary bile acids and
increased C. difficile fecal colonization, which agrees with the
general findings of the current study (6–9). Differences in specific bile acids between this study and murine studies likely reflect
both species differences (murine bile acids exhibit substantial
6-hydroxylation compared with humans) and different analytical
approaches. Human cells synthesize and chemically conjugate
bile acids, whereas intestinal microbes have been shown to modify them through dehydroxylation at the 7-carbon position to yield
deoxycholic and lithocholic acids (from cholic and chenodeoxycholic acids, respectively). Here, unbiased detection of 2 cholenic
acids (cholenic and hydroxycholenic acids, Supplemental Figures
6–11 and Supplemental Table 3) by GC-MS profiling as the most
highly CDI-associated bile acids raises the possibility that beneficial microbes can also dehydroxylate bile acids at the 3-carbon
position, leaving behind unsaturated, nonhydroxylated bile acids.
Detection of monohydroxycholenic acid sulfate (MHCE-S1, Table
3) provides additional evidence of this pathway. Five additional
bile acid sulfate candidates may represent either cholenic acids
jci.org   Volume 129   Number 9   September 2019
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Figure 8. Principal component analysis of GC-MS–defined metabolome in the clinical cohort. (A) Depicted here is a PCA plot of uninfected patients’
GC-MS metabolomes (green, n = 62), onto which is projected the GC-MS metabolomes of patients with CDI (red, n = 62). Data ellipses are drawn around
each group of samples (95% level). The clustering of CDI specimens at high PC1 values is consistent with a favored metabolomic profile among patients
with CDI. (B) Dot plot of PC1 scores for each patient (n = 62 in each group). Gray dashed line depicts the PC1 threshold that maximizes the sum of percent
sensitivity and specificity for distinguishing Cx–/EIA– from Cx+/EIA+ samples. (C) ROC plot evaluating the ability of PC1 to distinguish between CDI patients
and controls. The gray region represents 95% confidence intervals bootstrapped for the true-positive rate at each possible false-positive rate. An asterisk
marks the point corresponding to the optimal PC1 threshold depicted in panel B. (D) Plot of PC1 and PC2 loadings for all 2539 GC-MS features. It depicts the
relative contributions of each GC-MS feature to the distribution of Cx–/EIA– samples in the PCA projection in A. Features in the top or bottom 1% of PC1
loadings tentatively identified as sugars or sugar alcohols are highlighted in blue.

or keto-bile acids, both of which would exhibit ions 2 mass units
below their canonical counterparts. It remains unclear whether cholenic acids are solely CDI-negative patient biomarkers or
whether their formation protects patients from CDI (34). Production of these bile acids might confer CDI protection through consumption of progermination bile acids or by direct inhibition of C.
difficile spore germination. Additional experimental work is necessary to evaluate these possibilities and could help identify desirable microbiome constituents for future therapeutic strategies.
The biochemical signatures resolved in this study suggest a
metabolomic model of human CDI. In addition to identifying therapeutic strategies, such a model may also identify new or refined
diagnostic approaches to appropriately identify patients who
would benefit from treatment. Current diagnostic approaches are
based on nucleic acid–based detection of toxigenic C. difficile and
immunoassay-based detection of fecal toxin, each of which raise
valid concerns over their associated false-positive and false-negative rates (3, 10, 36). The metabolomic profiles identified in the
current work are biochemically distinct from existing tests and, in
a multistep diagnostic approach with existing tests, could improve
diagnostic accuracy. Detection of Stickland metabolites would be
consistent with the presence of antibiotic-responsive, vegetatively
3802
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growing C. difficile. Moreover, individualized metabolomic information on whether an unfavorable bile acid profile is present could
guide microbiome-directed interventions such as fecal transplant
or probiotic administration. The signatures identified here may aid
larger patient studies aimed at assessing the value of this approach.
In summary, this metabolomic study suggests specific host,
pathogen, and microbiome factors associated with CDI pathogenesis. Strengths of this study include use of a valid clinical study population with relevant control specimens and comparison to clinically
accessible test results, use of an unbiased screening approach, use
of multiple mass spectrometric methods, and use of strategies to

Table 4. Logistic regression model of CDI metabolome
Parameter

Crude odds ratio
(95% CI)

Adjusted

P valueA

Log10(4-MPA index)
Bile acid PC1

2.09 (2.01–6.06)
0.15 (0.01–0.30)

4.06 (2.15–7.53)
0.71 (0.31–1.42)

<0.0001
0.033

Analysis of deviance comparison between single-parameter logistic
regression model and the null logistic regression model.

A
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Figure 9. Interrelationships between host- and C. difficile–associated metabolites. (A) Plotting bile acid PC1 (Figure 7) versus 4-methylpentanoic acid index
(Figure 4) reveals that high PC1 score and high 4-methylpentanoic acid index values coincide in patients with CDI compared with control patients (n = 32 for each
group). The dashed line marks the dividing line assigned 50% probability of being Cx+/EIA+ by a logistic regression model incorporating both PC1 and 4-methylpentanoic acid index. (B) Probabilities assigned to each patient by the logistic regression model (n = 32 per group). Higher values indicate higher certainty of Cx+/
EIA+ status. The gray line marks the 50% probability cutoff above which samples are considered Cx+/EIA+. (C) ROC curve showing the performance of the logistic
regression model in discriminating Cx–/EIA– patients from Cx+/EIA+ patients. The gray region represents 95% confidence intervals bootstrapped for the true-positive rate at each possible false-positive rate. The AUC and its 95% confidence interval are also reported. (D) Euler diagram showing the overlap between culture,
EIA, and metabolome status. Samples were considered metabolome-positive if assigned a probability above 50% by the logistic regression model.

avoid the overfitting issues inherent in many comparative metabolomic approaches. The uniquely high chromatographic resolution
and informative electron ionization spectra of GC-MS analysis was
likely essential to our detection of 4-MPA, allo-isoleucine, and cholenoic acid, analytes that are poorly detected or resolved under typical LC-MS conditions. Moreover, the ability to identify metabolites
using spectrally rich EI fragmentation spectra in GC-MS allowed
us to place our analytic findings within a broader biological context. GC-MS is, however, restricted to small thermostable analytes,
a notable limitation of this modality when compared with LC-MS.
Other limitations of this study include its observational nature, lack
of longitudinal data, lack of nondiarrheal control specimens, and
insensitivity to host and pathogen-derived macromolecules (proteins, complex lipids, etc.). This work identifies a potential diagnostic approach to CDI as well as new hypotheses for future evaluation
regarding host bile acid networks’ interaction with CDI.

Methods

Patient specimen collection. This cohort was derived from samples submitted for physician-ordered C. difficile toxin testing as part of routine
clinical care. Remnant specimens that would have been otherwise discarded were frozen at –80°C by the laboratory for future use. Approval
was obtained from the Washington University Institutional Review

Board with a waiver of informed consent to use specimens for this
study. Patient and specimen evaluation for this cohort has recently
been described (14). From August 2014 through September 2016, the
Barnes-Jewish Hospital (BJH) Microbiology Laboratory detected the
presence of toxin A and B in these specimens using the Alere TOX A/B
II toxin enzyme immunoassay (EIA).
Inclusion and exclusion criteria. To identify and exclude patients with
a potential alternate cause of diarrhea, BJH medical informatics databases were queried to identify patients with these conditions and medications. Patient charts lacking an identifiable alternate cause of diarrhea
were reviewed to determine whether the patient had clinically significant diarrhea, and to confirm that there were no other known causes
of diarrhea. If it was not possible to determine whether the patient had
clinically significant diarrhea based on the medical records, the specimen was excluded. Specimens that were toxin negative (EIA–) were also
excluded if the patient received treatment for CDI within 14 days of stool
specimen collection. Due to these rigorous criteria, patients that were
toxin positive (EIA+) were considered to have CDI and patients who were
EIA– but positive for a toxigenic strain of C. difficile (defined by the presence of tcdA and/or tcdB by PCR; Cx+) were considered colonized with
toxigenic C. difficile but with diarrhea due to other reasons. EIA– stools
were also excluded if the patient was receiving antibiotics that could treat
CDI to better ensure that patients with Cx+/EIA– stool did not have CDI.
jci.org   Volume 129   Number 9   September 2019
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C. difficile culture and characterization. Briefly, 1 g stool was heat
shocked at 80°C for 10 minutes. The specimen was then placed into
cycloserine, cefoxitin, mannitol broth with taurocholate and lysozyme
(Anaerobe Systems) and incubated anaerobically at 35°C. When turbid, broth was streaked onto prereduced blood agar (BAP, Becton,
Dickinson and Company). C. difficile was identified by matrix-assisted
laser desorption/ionization time of flight (MALDI-TOF MS). Isolates
were evaluated for the presence of tcdA, tcdB, and binary toxin genes
(cdtA/cdtB) by multiplex PCR. PCR ribotyping was then performed.
The ribotyping banding patterns were analyzed using DiversiLab
Bacterial Barcodes software. Similarity of at least 95% was required
for isolates to be considered identical. All unique strains were compared with the Cardiff-ECDC collection of C. difficile strains for name
assignment. Isolates that did not match to a strain in the Cardiff-ECDC collection were compared with unique strains in the Washington University collection for name assignments. Isolates that did not
match strains in the Cardiff-ECDC collection or Washington University collection were assigned a unique name.
Fecal extracts. Stool specimens were thawed on ice and approximately 0.1 mg of each was transferred to a microfuge tube and
weighed. MeOH (1.25 mL, 70%) was added to each stool sample. The
samples were sealed with parafilm, vortexed for 10 seconds, and rotated in a cold room for 2 hours. The samples were vortexed, decanted
into a microcentrifuge tube and centrifuged at 20817 × g in a desktop
centrifuge for 15 minutes at 4°C. The supernatant was decanted into a
tube and stored at –80°C until analysis.
Gas chromatography–mass spectrometry (GC-MS). Stool extract
(30 μL) was pipetted into a glass vial, dried under N2, and derivatized
with 100 μL MSTFA (N-Methyl-N-trimethylsilyltrifluoroacetamide)/
CH3CN/pyridine(1:2.6:0.4), heated at 70°C for 30 minutes, then
cooled at room temperature overnight. Derivatized samples were
analyzed using an Agilent 7890A gas chromatograph interfaced to
an Agilent 5975C mass spectrometer and equipped with an HP-5MS
column (30 m, 0.25 mm i.d., 0.25 μm film coating). For GC, an initial
temperature of 80°C for 2 minutes was followed by a linear gradient
to 300°C at 10°C/minute followed by a 5-minute elution at 300°C. EI
was conducted with source temperature, electron energy, and emission current of 250°C, 70 eV, and 300 μA, respectively. The injector
and transfer line temperatures were 250°C. For metabolite profiling
and spectral analysis, the quadrupole was scanned from 50 to 650 m/z
units. Structural information about GC-EI-MS features was obtained
through spectral matching with the NIST 14 spectral library.
For targeted analyses of specific metabolites, the mass spectrometer monitored specific diagnostic ions for each compound. Each targeted metabolite was quantified in the selected ion monitoring mode
in which ion chromatogram peak areas were determined at their corresponding retention times (Supplemental Tables 2 and 3). For trehalose, stable isotope-labeled 13C-trehalose was added to each specimen
as an internal standard before derivatization (37). The peak areas of
trehalose and 13C internal standards were calculated as a ratio (Supplemental Figure 15).
Measurement of bile acids by liquid chromatography-mass spectrometry. LC-ESI-MS/MS detection of each bile acid in fecal specimens or
reference standards was performed with a Shimadzu UFLC coupled to
a BetaSil C18 HPLC column (50 mm × 2.1 mm × 3 μm; Thermo Fisher
Scientific) and an AB Sciex API 4000 QTrap mass spectrometer (AB
Sciex) running in negative-ion electrospray ionization mode (ESI)
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using a Turbo V ESI ion source. Authentic bile acid standards (Table 3)
were purchased and used to prepare 1 μM samples in 80% methanol.
HPLC was conducted with a 0.4 mL/min flow rate using the following
gradient: Solvent A (0.1% formic acid) and Solvent B (90% acetonitrile with 0.1% formic acid) were held constant at 95% and 5%, respectively, for 1 minute. Solvent B was increased to 98% by 8 minutes, held
at 98% for 1 minute, and then reduced again to 5% in 1 minute. The
column was equilibrated in 5% Solvent B for 3 minutes between runs.
Optimized instrument settings are reported in Supplemental Table 4.
Data preparation. Ion chromatograms were used to align peaks
and determine peak areas using Mass Profiler Professional software
(Agilent) for GC-MS data and Analyst (AB Sciex) for LC-MS/MS data
from the QTrap. Because of the large dynamic range and strong skew
of feature intensities, we transformed observed signals at level x to
log10(1+x) values prior to multivariate analyses.
Sparse logistic regression. We use the framework of logistic regression models to classify samples using their measured metabolomic
features. Since there are many more metabolomic features than there
are samples, we employed multiple measures to avoid overfitting the
data. First, we enforced sparsity with an L1 penalty on the number of
parameters selected as shown in Equation 1.

					(Equation 1)

Equation 1. This analysis is incorporated as part of the python module scikit-learn (38). The L1 penalty introduces a trade-off between
model goodness of fit and the number of incorporated features that is
tunable by an additional penalization parameter, C, in Equation 1. Second, we evaluated model performance using repeated 5-fold cross-validation with random subsets to optimize the sparsity penalty, as well as
to identify which features were used most frequently and were consistently predictive on the hold-out (testing) sets. Because overfitting on
training data is generally expected to reduce performance on a holdout set, this procedure allowed us to identify the penalization level that
maximizes expected performance on the testing set.
Finally, we obtained the 6-feature logistic regression described
in the main text though combination of the results from our repeated 5-fold cross-validated L1-penalized regressions, selecting the 6
metabolomic features most frequently obtained in these sparse logistic regressions. Using only those 6 features, we performed logistic
regression (not L1-penalized) on the 124 samples, obtaining the 96.7%
AUC in Figure 2D. We established 95% confidence intervals by further
5-fold cross-validation, keeping the 6 features fixed but varying their
coefficient contributions according to each training subset, yielding
the 95% CI: 85.6%–100%.
By way of contrast, we compared these results to a logistic regression performed on the full set of features without any sparsity criteria.
As expected, since there are an order of magnitude more features than
samples, it was possible to select regression coefficients that perfectly
separate (AUC = 1) the 2 classes in this case. However, this separation
is potentially meaningless because of overfitting. Similarly establishing a 95% confidence interval by 5-fold cross-validation, using all
metabolomic features, yields the 95% CI: 84.6%–99.5%. While this
is still very high—and indeed, is comparable to the CI for our regres-
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sion using only 6 features—the outlier nature of the artificial perfectly
separated result trained using all of the data is a warning of possible
overfitting. At the same time, we noted that even with this potential for
overfitting using all of the data, it performed no better than our 6-feature regression in terms of CI, while the 6-feature model of course provided much greater ease of interpretation.
We noted that this regression analysis on log-transformed signals
does not normalize across samples, nor employ methods to treat the
data in a compositional framework, despite the fact that relative abundances of metabolites are the biologically meaningful quantity. Nevertheless, this analysis successfully identifies features whose ratios are
informative in predicting classes (see main text).
Sparse partial least squares–discriminatory analysis (sPLS-DA). To
further assess the consistency of our data analysis results, we employed
sPLS-DA to find a low-rank approximation of the feature data set that
aims to maximally preserve the covariance between the dependent
variable (EIA status) and the independent variables (the features) (39,
40). This technique identifies a matrix decomposition similar to PCA
that best explains the relationship between the variables of interest
using the fewest number of features possible. This analysis was conducted using the R package mixOmics (41). We conducted both singleand multivariable prediction using sPLS-DA. PLS-DA attempts to find
a single decomposition of both the observations and the variable of
interest such that the covariance between the projected observations
and the projected variables is maximized in the projected space. In
this setting with many more features than observations (p >> n), there
are typically many low-dimensional combinations of features that
can capture variation in the variable of interest; moreover, these combinations will be typically dense in the sense that most features will
appear with small but nonzero contributions to prediction. In contrast,
the sparse version of PLS-DA, sPLS-DA, simultaneously models the
observations while performing feature selection by maximizing the
original objective function under conditions to minimize the number
of features incorporated.
Network-based analysis of bile acids. The network representation
of detected bile acids was defined here using the correlations across
all 186 samples as edge weights, keeping the 5 highest positive cor1. Lessa FC, et al. Burden of Clostridium difficile
infection in the United States. N Engl J Med.
2015;372(9):825–834.
2. Magill SS, et al. Changes in prevalence of health
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relations associated with each bile acid (5 nearest neighbors). Communities were detected from this network using the GenLouvain and
CHAMP packages (31, 42, 43). We selected the obtained 7-community
partition for visualization in Figure 6A, with the network layout produced by the ForceAtlas2 algorithm in Gephi (http://gephi.org) (44).
Study approval. Approval was obtained from the Washington University Institutional Review Board with a waiver of informed consent
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